I have dug a little deeper and my CRP tests have all been hs-CRP. My lowest was 0.7 in 2018. Crissman Loomis says daily walking is a great way to lower it.
1 Like
The last one was a CCTA. I do seem to have plateaued after possibly backing it up a little in 2022. I did keto and a huge amount of exercise back then, getting my 2 mile down to about 15 minutes. I think it made my CAC worse, donāt know about my ACM. I started having injuries and really canāt run like that any more. Recently got PRP for my labrum and should be better in a couple months.
The only explanation I have is hugely unpopular here. I tested high for lead and used every form of chelation I could find. High heavy metal load causes heart disease. I think it helped several of my issues and I may be on the mend now for good. My LDL has not moved in the entire time. Always between 160 and 130. I tried statins, Repatha, ezetimbe (I use it now off and on and it works some), and now Leqvio but will soon quit it because it doesnāt work at all. I know I could get the LDL down with drugs if I put my mind to it. Iām not sure it needs to be lower and defer to the judgement of my ancestral DNA.
it is the test that is high sensitivity not the CRP.
Although obicetrapib has no effect on hs CRP, it is today given marketing approval in the EU
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for UbesloĀ® (Obicetrapib Monotherapy) and EvlarcoĀ® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) ā NewAmsterdam Pharma
2 Likes
The European Commission approval follows the positive opinion adopted by the European Medicines Agencyās Committee for Medicinal Products for Human Use (CHMP) and is supported by data from NewAmsterdamās comprehensive clinical development program evaluating obicetrapib, including the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo and approximately 50% with obicetrapib combined with ezetimibe versus placebo, with a tolerability profile comparable to placebo. NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib through multiple ongoing Phase 3 trials, including PREVAIL, a cardiovascular outcomes trial, as well as REMBRANDT and RUBENS.
3 Likes
I walk daily, averaging 9000 + steps, and my hsCRP is 0.2 - could be connected to staying active.
2 Likes
It appears that low levels of hsCRP and IL-6 are not meaningfully protective against MACE. It remains the case that higher levels are worse, but low levels are not protective.